The abstracts are based on international studies including the comprehensive US SWOG study, the European prospective PYTHIA study, the PROMISE study at the
“It is extremely gratifying that DiviTum®TKa is included in four posters at SABCS. It is an important validation of our test as a possible standard tool in the evaluation of treatment effect in metastatic breast cancer. The results from the SWOG study are the backbone of our ongoing FDA 510 (k) application with the goal of making the test available to US patients in early 2021,” said
The San Antonio Breast Cancer Symposium, SABCS, runs
© Modular Finance, source